New obesity drug BGM0504 tested for interactions with metformin and warfarin

NCT ID NCT06920056

Completed Knowledge-focused Sponsor: BrightGene Bio-Medical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed Phase 1 trial tested how a new injectable drug, BGM0504, affects stomach emptying and the absorption of two common medications—metformin and warfarin—in 28 overweight or obese adults. Participants received BGM0504 alongside these drugs to measure changes in drug levels in the blood. The goal was to gather safety and interaction data, not to treat obesity directly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BGM0504
What this could lead to: If successful, this could help doctors understand how BGM0504 interacts with common medications, guiding safer use in people with obesity.
What could go wrong: This is an early Phase 1 trial with only 28 participants, focused on drug interactions rather than treatment outcomes. Results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT OR OBESE

Contacts and locations

Locations

The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine (Yunnan Provincial Hospital of Traditional Chinese Medicine)

Kunming, Yunnan, 650100, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.